

BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma

evo™ Smart Shipper, biologistex™ SaaS and MNX's Managed Logistics Service Provide Best-in-Class Solution for Shipping Apheresis Starting Material for Manufactured Cell Product

BOTHELL, Wash. and IRVINE, Calif., May 19, 2016 /PRNewswire/ -- [BioLife Solutions](#), Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue [hypothermic storage](#) and [cryopreservation freeze](#) media and a related [cloud hosted biologistics cold chain management app](#) for [smart shippers](#) ("BioLife" or the "Company"), today announced that through its biologistex joint venture, it will partner with MNX Global Logistics to support the registrational phase 3 clinical trial being conducted by ImmunoCellular Therapeutics (NYSE MKT: IMUC) for their ICT-107 dendritic cell-based immunotherapy for newly diagnosed glioblastoma.

MNX will use the biologistex evo Smart Shipper and biologistex cold chain SaaS to offer an enhanced managed logistics service for shipping the apheresis starting material, from which the ICT-107 dendritic cell-based therapy is manufactured to produce a personalized treatment for each patient in the clinical trial.

Marta Schilling, Vice President, Cell Therapy Manufacturing at ImmunoCellular Therapeutics, commented on their selection of this integrated solution by stating, "We have been well served by MNX for years. Through their partnership with BioLife, we were introduced to the evo Smart Shipper and biologistex cold chain SaaS. This is a state-of-the-art approach that we will use to enhance MNX's logistics services to ensure that our time and temperature-sensitive apheresis starting material arrives intact and according to specifications at our clinical manufacturing partner sites."

Mike Rice, BioLife President & CEO, commented, "We are very pleased to partner with MNX to enable a higher level of quality assurance in the cold chain logistics practices of ImmunoCellular for their registrational phase III trial. We commend ImmunoCellular for being an early adopter of evo and biologistex and believe we can drive adoption to become a best practice in the regenerative medicine industry."

Larry Glasscock, MNX Senior Vice President, remarked, "This is an early example of how MNX can leverage our existing relationships to increase awareness for evo and biologistex. BioLife recently reciprocated and introduced MNX to a BioLife cell therapy customer, and we see a great opportunity to cross-promote our complementary product and service offerings in our target markets."

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The phase 3 registrational trial of lead product candidate, ICT-107, a patient-specific, dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells, is open for patient screening. ImmunoCellular's pipeline also includes: ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells. To learn more about ImmunoCellular, please visit www.imuc.com.

About MNX Global Logistics

MNX is a premier global provider of specialized, expedited transportation and logistics services. Clients include multinational leaders in the aviation, life science, medical device, secure custody and control, technology, luxury fashion and entertainment industries. These organizations rely on MNX's exceptional record of transporting critical items around the world. www.mnx.com

About BioLife Solutions

BioLife Solutions develops, manufactures and markets biopreservation media products and smart shipping containers connected to a cloud hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability

and function of cells, tissues, and organs.

Our [biologistex](#) cloud based cold chain management service is an integrated logistics and tracking and trace web app used by shippers of time and temperature sensitive biologic materials. The [evo Smart Shipper](#) is a state of the art precision thermal shipping container with embedded payload monitoring, GPS location tracking, and cellular communication electronics that transmit critical shipment information to the cloud. This SaaS app enables users to monitor high value shipments during transit and configure actionable alerts for downstream recipients for location, approaching destination, delivery, package open, and remaining shelf life or stability via the patent pending StableAlert™ countdown timer. For more information please visit www.biolifesolutions.com, and follow BioLife on [Twitter](#).

This press release contains forward-looking statements, including, but not limited to, statements concerning new products, the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, market adoption of biologistex, commercial manufacturing of our customers' products, potential proceeds from the credit facility, and projected financial results, cash flow and liquidity, including the potential for reaching positive cash flow from operations next year. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Media & Investor Relations

Roderick de Greef
Chief Financial Officer
(425) 686-6003
rdegreef@biolifesolutions.com

SOURCE BioLife Solutions, Inc.

<https://investors.biolifesolutions.com/2016-05-19-BioLife-Solutions-and-MNX-Global-Logistics-Partner-to-Support-ImmunoCellular-Therapeutics-with-Cold-Chain-Logistics-in-ICT-107-Phase-3-Clinical-Trial-in-Glioblastoma>